Michael Evans - Profile and Investment Details

Investor Profile

Michael Evans is a Private Equity Firm based in United Kingdom with a diverse investment portfolio that includes companies such as Blackstone Technology Group, Detector Technology, Dynex Technologies, New England Peptide, LightPointe, Adaptas Solutions, MedPharm, CoreLab Partners, CRI Lifetree, N2 Biomedical LLC, Agilux Laboratories, Silicon Wave, ALPCO Diagnostics, ProGene Biomedical, Cequent Pharmaceuticals, ACLARA BioSciences, TriPath Imaging, FirstRain, Ampersand Capital Partners, Proficiency, Vibalogics, Brammer BioCorpus Medical, GeneWerk, Bioventus, Magritek Ltd, Chantest, Oxford Gene Technology, LakePharma, Ascot plc, Magellan Diagnostics, Innovative Food Processors, Signature Genomic Laboratories, Endeca, Viracor-IBT Laboratories, Institute of Directors, Panacos Pharmaceuticals, vivitide, Confluent Medical Technologies, Viadux, Talecris Biotherapeutics, RadPharm, Tjoapack Netherlands B.V., Canopy Biosciences, Nitinol Devices & Components, Azurity Pharmaceuticals, Sanova Dermatology, TAP Biosystems plc (formerly The Automation Partnership), Ensemble Communications, BioClinica, MedVenture Technology, Ortho Organizers, Nexelis, Interpace Diagnostics, Assay Designs, NutraMed, Roadrunner Pharmacy, Avista Pharma, Blue Sky Biotech, Alcami, Medifacts International, Elite One Source Nutritional Services, Genome Diagnostics (GenDx), GENEWIZ, Arranta Bio, Stereotaxis, Bako Diagnostics, ETE Medical Inc, StageBio, Cyclis Pharmaceuticals, Nexcelom Bioscience, Genoptix, . Over time, Michael Evans has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Michael Evans is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Telecommunications, Genetics, Women Founded, Life Science, Information Technology (IT), Software, Manufacturing, Biotechnology, Genomics, Medical, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Michael Evans, as their portfolio suggests a familiarity and interest in this area.

Understanding Michael Evans’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.